A Phase II Study of Xisomab 3G3, a Monoclonal Antibody Preventing the Activation of FXI by FXIIa, for the Prophylaxis of Catheter-Associated Thrombosis
Latest Information Update: 26 Jan 2024
At a glance
- Drugs Xisomab 3G3 (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- 01 Jan 2024 Results evaluating the safety and efficacy of AB023, published in the Arteriosclerosis Thrombosis and Vascular Biology
- 07 Nov 2023 Status changed from recruiting to discontinued due to IP manufacturing issue.
- 13 Dec 2022 Results (n=11) presented at the 64th American Society of Hematology Annual Meeting and Exposition.